"Kupando has spent seven years building a therapeutic platform around the other branch: the innate immune system, the body's older, faster-responding first line of defence that most pathogens and cancer cells have become adept at evading."
"KUP101 is a dual Toll-Like Receptor agonist, specifically, a TLR 4 and TLR 7 agonist, formulated as two small molecules co-encapsulated in a liposomal delivery system. Toll-Like Receptors are pattern recognition proteins on immune cells that detect molecular signals from pathogens and trigger innate immune responses."
"The capital will fund a Phase 1b clinical study of KUP101 in patients with advanced solid tumours and accelerate preclinical work in infectious diseases, including antimicrobial-resistant infections."
Kupando, a biopharmaceutical company, secured an additional €10 million in Series A financing, bringing total Series A funding to €23 million. The round was led by Remiges Ventures and co-led by LifeCare Partners, with participation from existing and new investors. The company has developed a therapeutic platform targeting the innate immune system, the body's first-line defense mechanism that most pathogens and cancer cells evade. KUP101, a dual Toll-Like Receptor agonist combining TLR 4 and TLR 7 agonists in a liposomal delivery system, will advance to Phase 1b clinical trials in patients with advanced solid tumors. Funding will also accelerate preclinical work in infectious diseases, particularly antimicrobial-resistant infections, with support from Germany's Federal Ministry of Research.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]